Drugs / Tecarfarin

Trials 5 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04627116 Apr → Dec 2020 Lee's Pharmaceutical Limited Unknown No outcome recorded
Phase 1 NCT03652779 Jun 2018 → Oct 2019 Lee's Pharmaceutical Limited Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00431782 Dec 2006 → Oct 2007 atrial fibrillation ARYx Therapeutics Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00691470 May 2008 → Jun 2009 atrial fibrillation, atrial flutter, cardiomyopathy, myocardial infarction +1 ARYx Therapeutics Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT02522221 Jun 2018 → Mar 2019 thrombotic disease Espero Biopharma Unknown No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as tecarfarin “The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.” PMID 19738136 Sep 2009
3

NCT03652779

NCT02522221

NCT04627116

Known as 60 TIS 99 ChEMBL registry synonym — accepted as the source's own label CHEMBL2105664
Known as ATI-5923 “An Open-label, Phase 1, Sequential Cohort, Single-Dose Escalation Study to Assess the Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers” NCT03652779
3

“BACKGROUND: Tecarfarin (ATI-5923), a structural analog of warfarin, was designed to provide more uniform and stable anticoagulation.” PMID 36622539 Jan 2023

NCT00691470

NCT00431782

Known as ATI-5923 SODIUM SALT ChEMBL registry synonym — accepted as the source's own label CHEMBL2105664
Known as TECARFARIN SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL2105664
Known as Tecarfarina ChEMBL registry synonym — accepted as the source's own label CHEMBL2105664
Known as Tecarfarine ChEMBL registry synonym — accepted as the source's own label CHEMBL2105664
Action Inhibit “ATI-5923 is a selective, non-competitive inhibitor of vitamin K epoxide reductase.” NCT00431782
1

“Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor” CHEMBL2105664

Modality Small molecule CHEMBL2105664
Route Oral “ATI-5923 is a structural analog of warfarin that is being developed as an oral anticoagulant.” NCT00431782
Target VKORC1 “Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor” CHEMBL2105664